Remember what the morning mayor used to say: Every brand new day should be unwrapped like a precious gift. So what if a meeting or deadline has you vexed? That bigger picture counts. So grab your cup of stimulation or bottle of water - even if the Associated Press found that it, too, is loaded with your favorite medicines - and get caught up with us…

ImClone Systems and Bristol-Myers Squibb may test some US cancer patients for a tick-bite antibody that can cause severe allergic reactions with Erbitux, according to a study. Researchers found an antibody in some patients, particularly in southeastern states, that reacts against a sugar in Erbitux to make them allergic to the treatment. The antibody probably comes from being bitten by ticks, study senior author Thomas Platts-Mills tells Bloomberg News.

The most severe late-blooming flu season in a decade is spurring unexpected earnings growth for Roche, Glaxo and AstraZeneca, Bloomberg News writes. When the US and European flu seasons end, prescriptions for Roche’s Tamiflu may have surged 200 percent from last year, Craig Maxwell, a JPMorgan Chase analyst in London, tells the wire.

An FDA panel recommended an Amgen drug be approved for treating a rare blood-platelet illness, but sales restrictions would be included out of concern that the drug might contribute to other serious blood disorders, The Wall Street Journal writes. Amgen has proposed a risk-management program that would restrict distribution to doctors treating patients with the disorder in hopes it would discourage off-label use.